259 related articles for article (PubMed ID: 24006273)
1. Managing localized prostate cancer in the era of prostate-specific antigen screening.
Brooks JD
Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
[TBL] [Abstract][Full Text] [Related]
2. The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.
Schlomm T
Eur Urol; 2015 Aug; 68(2):214-5. PubMed ID: 25680240
[No Abstract] [Full Text] [Related]
3. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
Sayburn A
BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
[No Abstract] [Full Text] [Related]
4. Doing it right: how, not whether, to perform prostate-specific antigen screening.
Martin NE
Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
[No Abstract] [Full Text] [Related]
5. The dilemmas of prostate cancer screening.
Hugosson J; Carlsson SV
Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
[No Abstract] [Full Text] [Related]
6. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
Luján M; Páez Á
Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
[No Abstract] [Full Text] [Related]
7. First, do no harm.
Pimlott N
Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
[No Abstract] [Full Text] [Related]
8. Future of screening for prostate cancer.
Dahm P
BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
[No Abstract] [Full Text] [Related]
9. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
Roobol MJ
Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
[No Abstract] [Full Text] [Related]
10. Should we screen for prostate cancer? A re-examination of the evidence.
Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
[No Abstract] [Full Text] [Related]
11. Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Taneja SS
J Urol; 2015 Aug; 194(2):393-4. PubMed ID: 26195364
[No Abstract] [Full Text] [Related]
12. Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial.
Shoag J; Halpern J; Eisner B; Lee R; Mittal S; Barbieri CE; Shoag D
JAMA Oncol; 2015 Oct; 1(7):984-6. PubMed ID: 26291583
[No Abstract] [Full Text] [Related]
13. Healing or harming: the prostate cancer dichotomy.
Zarrabi A; Mark S
N Z Med J; 2020 Oct; 133(1523):12-15. PubMed ID: 33032299
[No Abstract] [Full Text] [Related]
14. Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group.
Catalona WJ
Oncology (Williston Park); 2014 Feb; 28(2):154, 156. PubMed ID: 24701705
[No Abstract] [Full Text] [Related]
15. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Taneja SS
J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
[No Abstract] [Full Text] [Related]
16. The dilemmas of prostate cancer screening.
Del Mar CB
Med J Aust; 2013 Nov; 199(9):584. PubMed ID: 24182218
[No Abstract] [Full Text] [Related]
17. The dilemmas of prostate cancer screening.
Hugosson J; Carlsson SV
Med J Aust; 2013 Nov; 199(9):583-4. PubMed ID: 24182217
[No Abstract] [Full Text] [Related]
18. The dilemmas of prostate cancer screening.
Lawrentschuk N; Murphy DG; Costello AJ
Med J Aust; 2013 Nov; 199(9):583. PubMed ID: 24182216
[No Abstract] [Full Text] [Related]
19. The dilemmas of prostate cancer screening.
Haines IE
Med J Aust; 2013 Nov; 199(9):582-3. PubMed ID: 24182215
[No Abstract] [Full Text] [Related]
20. The dilemmas of prostate cancer screening.
McKenzie PR; Delahunt B; Kench JG
Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
